Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China

Why It Matters

The data gives Regeneron a viable growth platform in the fast‑growing obesity market, helping offset recent setbacks with Dupixent and Eylea. Its improved tolerability could differentiate it in a crowded incretin space, attracting investors and partners.

Key Takeaways

• 19% average weight loss at 48 weeks.
• Lower GI adverse events than rival incretins.
• Trial met both co‑primary weight‑loss endpoints.
• Regeneron secured global rights for $80M upfront.
• Asset targets obesity, diabetes, dyslipidemia.

Pulse Analysis

The global obesity epidemic has turned weight‑loss drugs into multi‑billion‑dollar opportunities, with GLP‑1 and GIPR agonists leading the charge. While Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy dominate U.S. markets, Asian regulators are increasingly pivotal as they evaluate local trial data. Hansoh’s Phase 3 results not only demonstrate robust efficacy but also suggest a more favorable safety profile, a factor that could sway prescribers seeking alternatives to the nausea‑heavy class.

Olatorepatide’s 19% mean weight reduction over 48 weeks, coupled with gastrointestinal adverse events below 10% for nausea and 5% for vomiting, positions it as a potentially more tolerable option. The trial’s design—604 participants across three dose levels—provides a solid statistical foundation, meeting both co‑primary endpoints of absolute weight loss and the proportion achieving at least 5% loss. Such outcomes may appeal to payers and clinicians wary of discontinuations that plague existing therapies, potentially improving adherence and long‑term outcomes.

Strategically, Regeneron’s $80 million upfront deal, with up to $1.93 billion in milestones, signals confidence in the asset’s commercial upside beyond China. By planning a global late‑stage program, the company aims to leverage the drug’s multi‑indication potential—obesity, type 2 diabetes, and dyslipidemia—creating a diversified revenue stream. This move could revitalize investor sentiment after recent share declines tied to Dupixent setbacks, and it underscores Regeneron’s broader shift toward novel, non‑me‑too biologics in a competitive therapeutic landscape.